[144] Arcutis Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Arcutis Biotherapeutics (ARQT) filed a Form 144 reporting proposed and recent insider sales. The filing names common stock with a proposed sale of 9,625 shares through Merrill (Columbus, OH) with an aggregate market value of $168,800 and an approximate sale date of 09/08/2025 on NASDAQ. The shares were acquired as restricted stock that vested on 05/01/2025, totaling 9,625 shares. The filing also discloses a sale on 08/04/2025 by Todd Franklin Watanabe of 11,547 common shares for gross proceeds of $165,429. The filer certifies no undisclosed material adverse information.

Positive

• Required disclosure provided: The filing includes acquisition date, nature of acquisition (restricted stock vest), broker, and proposed sale details.
• Prior sale disclosed: A recent insider sale of 11,547 shares for $165,429 is reported, showing past transaction transparency.

Negative

• Insider selling activity: Proposed sale of 9,625 shares and a recent sale of 11,547 shares indicate insider dispositions which some investors may view negatively.

Insights

Securities Analyst

TL;DR: Routine insider transactions disclosed; sizes appear modest relative to public company scale.

The Form 144 documents a proposed sale of 9,625 vested restricted shares and reports a prior sale of 11,547 shares by an identified seller. Both transactions are presented as standard insider dispositions under Rule 144. The filing states the acquisition date for the proposed-sale shares as 05/01/2025 and the proposed sale date as 09/08/2025. No financial results, changes to management or other corporate events are disclosed in this filing, limiting material implications to ownership changes reflected by these specific share counts and dollar amounts.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; no red flags in the statement provided.

The notice includes required elements: acquisition method (restricted stock vest), acquisition date, number of shares, broker information, and a seller record for recent sales. The signer affirms absence of undisclosed material adverse information. The filing does not present evidence of coordinated or large-scale disposition beyond the reported amounts, and it does not reference a Rule 10b5-1 plan or other trading instructions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr th Flr Columbus OH 43240	9625	168800.00	119905078	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2025	Restricted stock vest	Arcutis Biotherapeutics			9625	05/01/2025	na

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd Franklin Watanabe 3027 Townsgate Rd sSe 300 Westlake Village CA 91361	common	08/04/2025	11547	165429.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Arcutis Biotherapeutics' Form 144 (ARQT) report?

The filing reports a proposed sale of 9,625 common shares (aggregate market value $168,800) and discloses a prior sale of 11,547 shares for gross proceeds of $165,429.

When were the shares proposed for sale acquired?

The shares proposed for sale were acquired on 05/01/2025 as restricted stock that vested on that date.

Who executed the recent sale disclosed in the filing?

The recent sale on 08/04/2025 was executed by Todd Franklin Watanabe, who sold 11,547 common shares.

Through which broker is the proposed sale to occur?

The proposed sale lists Merrill at the Columbus, OH address as the broker.

Does the filing indicate any undisclosed material information?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.